المؤلفون: Kochis, Michael, Bizimana, Christa, Zitsman, Jeffrey L, Pratt, Janey S A, Griggs, Cornelia L

المصدر: J Surg Res ; ISSN:1095-8673 ; Volume:301

مصطلحات موضوعية: Glucagon-like peptide-1 receptor agonist, Metabolic and bariatric surgery, Pediatric obesity, Pediatric surgery, Survey, Weight loss

الوصف: Glucagon-like peptide-1 receptor agonist (GLP-1A) medications are gaining widespread popularity for the treatment of obesity. The optimal use of these drugs in pediatric bariatric populations, and especially in those considering metabolic and bariatric surgery (MBS), is yet to be established. We sought to characterize current practice patterns of GLP-1A use at major pediatric bariatric centers across the United States.

العلاقة: https://doi.org/10.1016/j.jss.2024.05.045Test; https://pubmed.ncbi.nlm.nih.gov/38941713Test

الإتاحة: https://doi.org/10.1016/j.jss.2024.05.045Test
https://pubmed.ncbi.nlm.nih.gov/38941713Test

المؤلفون: Samuels, Jason M, Niswender, Kevin D, Roumie, Christianne L, Spann, Matthew D, Flynn, C Robb, Ye, Fei, Blankush, Joseph, Irlmeier, Rebecca, Funk, Luke M, Patel, Mayur B

المصدر: Diabetes Obes Metab ; ISSN:1463-1326

مصطلحات موضوعية: adjuvant weight loss therapy, bariatric surgery, glucagon‐like peptide‐1 receptor agonists, inadequate weight loss

الوصف: To compare the incidence of adverse events (AEs) related to antiobesity medications (AOMs; glucagon-like peptide-1 receptor agonists [GLP-1RAs] vs. non-GLP-1RAs) after bariatric surgery.

العلاقة: https://doi.org/10.1111/dom.15737Test; https://pubmed.ncbi.nlm.nih.gov/38934217Test

الإتاحة: https://doi.org/10.1111/dom.15737Test
https://pubmed.ncbi.nlm.nih.gov/38934217Test

المؤلفون: Liu, Ming, Gu, Weijun, Chen, Li, Li, Yanbing, Kuang, Hongyu, Du, Jianling, Alvarez, Agustina, Lauand, Felipe, Souhami, Elisabeth, Zhang, Jiewen, Xu, Weiya, Du, Qin, Mu, Yiming

المصدر: Diabetes Obes Metab ; ISSN:1463-1326

مصطلحات موضوعية: Chinese population, body weight, fixed‐ratio combination, glucagon‐like peptide‐1 receptor agonist, glycaemic control, hypoglycaemia, iGlarLixi, premixed insulin

الوصف: To compare the efficacy and safety of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin, insulin degludec plus insulin aspart (IDegAsp), in Chinese people with type 2 diabetes (T2D) suboptimally controlled with oral antidiabetic drug(s) (OADs).

العلاقة: https://doi.org/10.1111/dom.15724Test; https://pubmed.ncbi.nlm.nih.gov/38922731Test

الإتاحة: https://doi.org/10.1111/dom.15724Test
https://pubmed.ncbi.nlm.nih.gov/38922731Test

المؤلفون: Williams, David M, Alberts, Barbara-Alex, Sharaf, Asem, Sharaf, Giselle, Bain, Stephen C, Kalhan, Atul, Min, Thinzar

المصدر: Diabetes Ther ; ISSN:1869-6953 ; Volume:15 ; Issue:7

مصطلحات موضوعية: GLP-1, Glucagon-like peptide-1 receptor analogues, Real world, Semaglutide, Type 2 diabetes, Weight loss

الوصف: Oral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.

العلاقة: https://doi.org/10.1007/s13300-024-01590-xTest; https://pubmed.ncbi.nlm.nih.gov/38722497Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211302Test/

الإتاحة: https://doi.org/10.1007/s13300-024-01590-xTest
https://pubmed.ncbi.nlm.nih.gov/38722497Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211302Test/

المؤلفون: Wang, Vicki, Tseng, Kuan-Yin, Kuo, Tung-Tai, Huang, Eagle Yi-Kung, Lan, Kuo-Lun, Chen, Zi-Rong, Ma, Kuo-Hsing, Greig, Nigel H, Jung, Jin, Choi, Ho-Ii, Olson, Lars, Hoffer, Barry J, Chen, Yuan-Hao

المصدر: J Biomed Sci ; ISSN:1423-0127 ; Volume:31 ; Issue:1

مصطلحات موضوعية: Exenatide, Glucagon-like peptide-1 receptor agonist, MitoPark mouse, Mitochondria, PT320, Parkinson’s disease

الوصف: Mitochondria are essential organelles involved in cellular energy production. Changes in mitochondrial function can lead to dysfunction and cell death in aging and age-related disorders. Recent research suggests that mitochondrial dysfunction is closely linked to neurodegenerative diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonist has gained interest as a potential treatment for Parkinson's disease (PD). However, the exact mechanisms responsible for the therapeutic effects of GLP-1R-related agonists are not yet fully understood.

العلاقة: https://doi.org/10.1186/s12929-024-01025-6Test; https://pubmed.ncbi.nlm.nih.gov/38627765Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022395Test/

الإتاحة: https://doi.org/10.1186/s12929-024-01025-6Test
https://pubmed.ncbi.nlm.nih.gov/38627765Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022395Test/

المؤلفون: Zhao, Sizheng Steven, Burgess, Stephen, Gill, Dipender

المصدر: J Am Heart Assoc ; ISSN:2047-9980 ; Volume:13 ; Issue:12

مصطلحات موضوعية: diabetes, glucagon‐like peptide‐1 receptor antagonist, obesity, suicide, weight loss

العلاقة: https://doi.org/10.1161/JAHA.124.035948Test; https://pubmed.ncbi.nlm.nih.gov/38879463Test

الإتاحة: https://doi.org/10.1161/JAHA.124.035948Test
https://pubmed.ncbi.nlm.nih.gov/38879463Test

المؤلفون: Akhverdyan, Nazar, Wieland, Amanda, Sullivan, Shelby, Lindsay, Mark, Swartwood, Sheila, Arndt, Gretchen, Kaizer, Laura Katherine, Jensen, Thomas

المصدر: Metab Syndr Relat Disord ; ISSN:1557-8518

مصطلحات موضوعية: fibroscan, glucagon-like peptide-1 receptor agonist, metabolic dysfunction-associated steatotic liver disease, steatohepatitis, vibration-controlled transient elastography

الوصف: Introduction: Current guidelines recommend the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), especially in patients with comorbid diabetes and obesity. This study investigated the effects of GLP-1RAs on hepatic steatosis and fibrosis in patients with MASLD, as measured by changes in vibration-controlled transient elastography (VCTE) and other clinical parameters in a real-world clinical setting. Methods: We conducted a single-center, retrospective analysis of 96 patients with MASLD from a multidisciplinary care clinic who completed VCTE at baseline and follow-up within 6-24 months to compare changes in controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), as well as other metabolic markers, between GLP-1RA users and nonusers using two-sample t-tests and Wilcoxon rank-sum tests. We also assessed whether improvements in hepatic steatosis, defined as a change in CAP >38 dB/m as previously described in the literature, were associated with improvement in fibrosis. Results: GLP-1RA use resulted in significant improvements in weight (-8.1 kg vs. -3.5 kg, P = 0.009), body mass index (BMI) (-2.9 kg/m2 vs. -1.3 kg/m2, P = 0.012), alanine aminotransferase (-15.0 IU/L vs. -4.0 IU/L, P = 0.017), aspartate aminotransferase (-5.0 IU/L vs. -1.0 IU/L, P = 0.021), glycated hemoglobin (HbA1c) (-0.7% vs. 0.1%, P = 0.019), and CAP (-59.9 dB/m vs. -29.1 dB/m, P = 0.016). Responders also had significant improvements in weight (-9.2 kg vs. -1.9 kg, P < 0.001), BMI (-3.3 kg/m2 vs. -0.7 kg/m2, P < 0.001), diastolic blood pressure (-6.1 mmHg vs. -0.7 mmHg, P = 0.028), HbA1c (-0.8% vs. 0.3%, P < 0.001), and LSM (-1.5 kPa vs. 0.1 kPa, P < 0.001). Conclusions: Patients with MASLD treated with GLP-1RAs showed significant improvements in hepatic steatosis and multiple other metabolic parameters, with weight loss as the proposed mechanism for this liver improvement. In addition, change in CAP >38 dB/m was associated with improvements in LSM and other metabolic parameters, suggesting the clinical utility of VCTE in the surveillance of MASLD.

العلاقة: https://doi.org/10.1089/met.2024.0115Test; https://pubmed.ncbi.nlm.nih.gov/38868900Test

الإتاحة: https://doi.org/10.1089/met.2024.0115Test
https://pubmed.ncbi.nlm.nih.gov/38868900Test

المؤلفون: Marshall, Stacy, Ryan, Erin, Rivera, Jessica, Reynolds, Lindy, Atti, Suhkshant

المصدر: J Med Toxicol ; ISSN:1937-6995

مصطلحات موضوعية: Glucagon-like peptide-1 Receptor Agonist, Hypoglycemia, Overdose

الوصف: Glucagon-like peptide-1 receptor agonist use has increased over the last decade for glycemic control in type 2 diabetes mellitus, cardiovascular risk reduction, and weight loss. Clinical trials indicate that gastrointestinal adverse effects are commonly experienced and severe hypoglycemia is rare; however, there is little data regarding glucagon-like peptide-1 receptor agonist in overdose.

العلاقة: https://doi.org/10.1007/s13181-024-01008-xTest; https://pubmed.ncbi.nlm.nih.gov/38861153Test

الإتاحة: https://doi.org/10.1007/s13181-024-01008-xTest
https://pubmed.ncbi.nlm.nih.gov/38861153Test

المؤلفون: Hill, Alexander C, Santhanam, Prasanna, Samples, Caroline B, Mitsui Akagi, Roberto, Latif, Tariq, Khthir, Rodhan

المصدر: Cureus ; ISSN:2168-8184 ; Volume:16 ; Issue:5

مصطلحات موضوعية: diabetes type 2, glucagon-like peptide-1 receptor agonists, insulin regimen, insulin requirement, insulin-dependent diabetes mellitus

الوصف: Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant efficacy in improving glycemic control in type 2 diabetes mellitus, which often results in decreased insulin dose requirements. The purpose of this study was to examine the changes in basal and prandial insulin dose requirements from baseline to three months following initiation of a GLP-1 RA. Methodology A retrospective chart review was conducted of adult insulin-treated patients at the Chertow Diabetes Center, Huntington, WV, who were started on GLP-1 RAs for 24 months. Results Mean daily basal insulin doses decreased by 8.7 units (P = 0.29; mean 8.3% change) and mean daily prandial insulin doses decreased by 9.4 units (P = 0.10; mean 18.4% change) from baseline to three months after starting a GLP-1 RA. Average hemoglobin A1c significantly decreased from 8.8% (73 mmol/mol) at baseline to 8.0% (64 mmol/mol) at three months (P < 0.001). Significant decreases from baseline to three months were also observed in mean body weight, mean low-density lipoprotein (LDL) cholesterol, and mean total cholesterol. Conclusions GLP-1 RA therapy was associated with a significant decrease in hemoglobin A1c, body weight, and LDL-cholesterol from baseline to three months after initiation. Therapy with GLP-1 RAs was also associated with an overall decrease in daily basal and prandial insulin dose requirements, although this finding did not reach statistical significance.

العلاقة: https://doi.org/10.7759/cureus.59899Test; https://pubmed.ncbi.nlm.nih.gov/38854306Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160513Test/

الإتاحة: https://doi.org/10.7759/cureus.59899Test
https://pubmed.ncbi.nlm.nih.gov/38854306Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160513Test/

المؤلفون: de Oliveira Costa, Juliana, Lin, Jialing, Milder, Tamara Y, Greenfield, Jerry R, Day, Richard O, Stocker, Sophie L, Neuen, Brendon L, Havard, Alys, Pearson, Sallie-Anne, Falster, Michael O

المصدر: Diabetes Obes Metab ; ISSN:1463-1326 ; Volume:26 ; Issue:7

مصطلحات موضوعية: geographic variation, glucagon‐like peptide‐1 receptor agonists, pharmacoepidemiology, sodium‐glucose cotransporter 2 inhibitor, type 2 diabetes

الوصف: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and cardio-renal outcomes for people with type 2 diabetes (T2D). However, geographic and socio-economic variation in use is not well understood.

العلاقة: https://doi.org/10.1111/dom.15597Test; https://pubmed.ncbi.nlm.nih.gov/38618983Test

الإتاحة: https://doi.org/10.1111/dom.15597Test
https://pubmed.ncbi.nlm.nih.gov/38618983Test